allotrap has been researched along with Colitis, Granulomatous in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourreille, A; Buelow, R; de la Blétière, DR; Doubremelle, M; Galmiche, JP; Segain, JP; Toquet, C | 1 |
| Holtmann, MM | 1 |
| Hoffmann, JC | 1 |
1 review(s) available for allotrap and Colitis, Granulomatous
| Article | Year |
|---|---|
RDP-58 (SangStat Medical).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Peptides; Structure-Activity Relationship | 2003 |
1 trial(s) available for allotrap and Colitis, Granulomatous
| Article | Year |
|---|---|
RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease.
Topics: Adolescent; Adult; Aged; Animals; Anti-Inflammatory Agents; Colitis; Crohn Disease; Female; Histocompatibility Antigens Class I; Humans; Interferon-gamma; Interleukin-1; Intestinal Mucosa; Male; Middle Aged; Models, Animal; Peptides; Prospective Studies; Rats; Rats, Sprague-Dawley; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2003 |
1 other study(ies) available for allotrap and Colitis, Granulomatous
| Article | Year |
|---|---|
[Inflammatory bowel disease: anti-TNF strategies and beyond].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Infliximab; Intercellular Adhesion Molecule-1; Natalizumab; Peptides; Receptors, Interleukin-6; Signal Transduction; Tumor Necrosis Factor-alpha | 2004 |